Company: TELO
Filing Date: 2025-02-20
Form Type: 8-K
Source: 0001493152-25-007698
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-20
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO), or Telomir, a leader in age-reversal science breakthrough achievement captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically
compatible form advanced
antimicrobial treatments, wound care solutions, and infection-resistant medical coatings

Significance
of These Findings

Silver(II)
has long been recognized for its superior antimicrobial properties, stronger oxidative activity, and potential role in accelerating
tissue repair and reducing inflammation Silver(II) potently generates
reactive oxygen species (ROS), making it very effective against resistant bacteria and biofilms stimulates fibroblast
activity, promotes collagen production, and enhances blood vessel formation faster scarring, wound healing
and tissue regeneration positioned to pioneer next-generation topical wound
care and infection control therapies, creating new commercial opportunities in the medical and biotech sectors

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                         TELOMIR                                      
  Dated:                 By:                       /s/                
                         Name:                     Erez               
                         Title:                    Chief